New Standpoint of ALT Test for Blood Safety in Dongguan Blood Center


Objective: To investigate the relationship between the single ALT positive (ELSIA-HBV/HCV negative) and NAT-HBV/HCV on blood donor samples. Methods: 28710 samples were surveyed retrospectively from Dec. 2010 to Dec. 2011. ALT was detected by rate method, and the single ALT positive samples were detected by ELSIA-HBV/HCV and NAT-HBV/HCV. The relationship between the single ALT positive and NAT-HBV/HCV were analyzed. 21 samples, values in 40 U/L ≤ ALT ≤ 70 U/L, were selected at random from 2516 samples with single ALT positive, which were second detected by ELISA and NAT in the second donation. Results: 2516 (8.74%) single ALT positive samples (ELSIA-HBV/HCV negative) were found in 28710 donors. Among these samples, 8 (2.8/10000) positive were detected by NAT, including 5 HBV-DNA-positive and 3 HCV-RNA-positive. Obviously, positive rate of NAT from the donors whose ALT value ≤ 70 U/L were lower than those of ≥ 71 U/L (P < 0.01). 21 donors were investigated in the second donation in following 153 to 401 days, All samples were negative by ELISA-HBV/HCV and NAT-HBV/HCV. Conclusions: Donors with single ALT positive (value in 40 U/L-70 U/L) are not likely to become HBV/HCV virus carriers or HBV/HCV patients after half or one year. So it is to set ALT abandone threshlod to ≤ 70 U/L can ensure blood safety, and reduce blood abandone in our center.

Share and Cite:

He, Z. , Liu, F. , Wang, D. , Che, J. and Che, J. (2014) New Standpoint of ALT Test for Blood Safety in Dongguan Blood Center. Open Journal of Clinical Diagnostics, 4, 41-46. doi: 10.4236/ojcd.2014.41008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] European Commission, Enterprise Directorate-General; Working Party on Control of Medicines and Inspections. Revision Annex 14 of the EU Guide to Good Manufacturing Practice. Manufacture of Medicinal Products Derived from Human Blood or Blood Plasma. Brussels, European Commission [M].2000.58-64.
[2] Shindo, M., Di Bisceglie, A.M., Biswas, R., et al. (1992) Hepatitis C Virus Replication during Acute in Faction in the Chimpanzee [J]. The Journal of Infectious Diseases, 166, 424-427.
[3] Lee, D.H., Ha, M.H. and Christiani, D.C. (2001) Body Weight, Alcohol Consumption and Liver Enzyme Activity—A 4-Year Follow-Up Study [J]. International Journal of Epidemiology, 30, 766-770.
[4] Shakil, A.O., Conry-Cantilena, C., Alter, H.J., et al. (1995) Volunter Blood Donors with Antibody to Hepatitis Cvirus: Clinical, Biochemical, Virologic, and Histologic Features [J]. Annals of Internal Medicine, 123, 330-337.
[5] Alter, H.J., Conry-Cantilena, C., Melpoder, J., et al. (1997) Hepatitis C in Asymptomatic Blood Donors [J]. Hepatology, 26, 29-33.
[6] Sankary, T.M., Yang, G., Romeo, J.M., et al. (1994) Rare Detection of Hepatitis Band Hepatitis C Virus Genomes by Polymerase Chain Reaction in Seronegative Donors with Elevated Alanine Aminotransferase [J]. Transfusion, 34, 656-660.
[7] Notari 4th, E.P., Orton, S.L., Cable, R.G., et al. (2001) Seroprevalence of Known and Putative Hepatitis Markers in United States Blood Donors with ALT Levels at Least 120 IU per L [J]. Transfusion, 41, 751-755.
[8] Goncales Júnior, F.L., Stucchi, R.S., Papaiordanou, P.M., et al. (1998) Elevated Alanine Aminotransferase (ALT) in Blood Donors: An Assessment of the Main Associated Conditions and Its Relationship to the Development of Hepatitis C [J]. Revista do Instituto de Medicina Tropical de Sao Paulo, 40, 219-224.
[9] Kao, J.H., Chen, P.J., Lai, M.Y., et al. (2002) Genotypes and Clinical Phenotypes of Hepatitis Virus in Patients with Chronic Hepatitis B Virus Infection [J]. Journal of Clinical Microbiology, 40, 1207-1209.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.